Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
06 2022
Historique:
entrez: 1 7 2022
pubmed: 2 7 2022
medline: 6 7 2022
Statut: ppublish

Résumé

Compared with individuals unvaccinated in the current and three previous influenza seasons, in 2021/22, influenza vaccine effectiveness at primary care level was 37% (95% CI: 16 to 52) for current season vaccination, regardless of previous doses, and 35% (95% CI: -3 to 45) for only previous seasons vaccination. Against influenza A(H3N2), estimates were 39% (95% CI: 16 to 55) and 24% (95% CI: -8 to 47) suggesting moderate effectiveness of current season vaccination and possible remaining effect of prior vaccinations.

Identifiants

pubmed: 35775428
doi: 10.2807/1560-7917.ES.2022.27.26.2200488
pmc: PMC9248265
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Euro Surveill. 2022 Apr;27(15):
pubmed: 35426361
Vaccine. 2010 Oct 28;28(46):7381-8
pubmed: 20851086
Clin Infect Dis. 2014 Nov 15;59(10):1375-85
pubmed: 25270645
BMC Med. 2019 Jan 10;17(1):9
pubmed: 30626399
Clin Infect Dis. 2022 Mar 24;:
pubmed: 35325923
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):365-370
pubmed: 35271561
Euro Surveill. 2012 Apr 26;17(17):
pubmed: 22551499
Euro Surveill. 2022 Apr;27(15):
pubmed: 35426364
Euro Surveill. 2021 Aug;26(32):
pubmed: 34387185

Auteurs

Iván Martínez-Baz (I)

Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.

Itziar Casado (I)

Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.

Ana Miqueleiz (A)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.

Ana Navascués (A)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.

Francisco Pozo (F)

CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

Camino Trobajo-Sanmartín (C)

Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.

Esther Albéniz (E)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Gerencia de Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain.

Fernando Elía (F)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Gerencia de Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain.

Cristina Burgui (C)

Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.

Miguel Fernández-Huerta (M)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.

Carmen Ezpeleta (C)

Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.

Jesús Castilla (J)

Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH